Intellia Therapeutics ( (NTLA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Intellia Therapeutics’ stock price took a hit following the company’s announcement of a temporary pause in its MAGNITUDE and MAGNITUDE-2 Phase 3 trials. The pause was due to a severe liver issue in a patient, raising concerns about the trial’s future among investors. Intellia is actively working with regulatory authorities to address the issue and ensure patient safety, but the uncertainty has already impacted the stock’s performance.
More about Intellia Therapeutics
YTD Price Performance: 109.49%
Average Trading Volume: 5,647,273
Technical Sentiment Signal: Hold
Current Market Cap: $2.75B
For further insights into NTLA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.